Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony rozpoznaniem raka płuca bez drobnych komórek, stadium III
- •Guz nadaje się do usunięcia chirurgicznego
- •Bez wcześniejszego leczenia raka
- •Ogólny stan zdrowia dobry (skala ECOG 0-1)
- •Prawidłowe wyniki badań krwi i funkcji nerek
- •Kobiety w wieku rozrodczym - ujemny test ciąży
- •Możliwość podpisania zgody i uczestnictwa w badaniu
✗ Disqualifies
- •Poprzednie leczenie tego raka (chemioterapia, radioterapia, immunoterapia)
- •Mutacja genu EGFR, przebudowa ALK lub inne specyficzne zmiany genetyczne
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Qilu Hospital of Shandong University
Jinan, China
Trial contact
Yanguo Liu
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.